Procter & Gamble Health Ltd

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has announced its unaudited financial results for the quarter ended September 30, 2026, with sales up 18% and PAT up 26% compared to the same period last year.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has announced its unaudited financial results for the quarter and half year ended September 30, 2026. The company's revenue from operations was ₹38.249 crores, with a total income of ₹316.31 crores. The company's expenses included cost of materials consumed, purchases of stock-in-trade, changes in inventories, employee benefits expenses, depreciation and amortisation expenses, finance costs, and other expenses.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has announced its unaudited financial results for the quarter and half year ended September 30, 2026. The company's revenue from operations was ₹38.249 lakhs, and its total income was ₹36.371 lakhs. The company's expenses included cost of materials consumed, purchases of stock-in-trade, changes in inventories of finished goods, work-in-progress and stock in trade, employee benefits expenses, depreciation and amortisation expenses, and finance costs.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has confirmed compliance under Regulation 74(5) of the SEBI (DP) Regulations for the quarter ended September 30, 2026, by furnishing details of securities dematerialized during the quarter to the stock exchanges.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has scheduled a Board of Directors meeting on November 2, 2026, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2026.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd announces closure of trading window for directors and designated employees from October 1, 2026, until 48 hours after unaudited financial results for Q2FY27 are published.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has informed the stock exchange about an update on Ease of doing Investment - Special Window for Transfer and Dematerialization. SEBI has extended the timeline for re-lodging transfer requests for physical shares lodged prior to April 01, 2019, and rejected/returned/not attended to due to deficiency in documents/process.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has announced the re-appointment of Mr. S. Madhavan as Independent Director for a period of 5 years, effective November 15, 2026, following approval by shareholders at the 59th Annual General Meeting on September 3, 2026.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has announced the results of its 59th Annual General Meeting (AGM), which was held on September 3, 2026. The meeting saw a total of 5 resolutions being passed, including the appointment of a new director, ratification of remuneration payable to the Cost Auditor, and confirmation of payment of interim dividend and declaration of Final Dividend for the Financial Year ended March 31, 2026.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd held its 59th Annual General Meeting on September 3, 2026, through video conference. The meeting approved the audited balance sheet, statement of profit and loss, and auditors' reports. The company also declared interim and final dividends, appointed a new director, and ratified the remuneration of the cost auditor. The meeting concluded with the announcement of the voting results to be made available on the company's website within 2 working days.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has announced the 59th Annual General Meeting (AGM) for the Financial Year ended March 31, 2026, scheduled on September 3, 2026, at 2:30 PM. The AGM notice and annual report have been sent to shareholders via email and are also available on the company's website.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has released its Business Responsibility and Sustainability Report for the Financial Year ended March 31, 2026, which forms part of the Annual Report for the Financial Year ended March 31, 2026.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has announced the release of its Annual Report for the Financial Year 2025-26, ahead of its 59th Annual General Meeting scheduled on September 3, 2026.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has announced its Annual Report for the Financial Year 2025-26 and Notice calling the 59th Annual General Meeting of the Company, scheduled on September 3, 2026. The report includes financial highlights, director's report, business responsibility & sustainability report, and corporate governance report. Shareholders can register to express their views or ask questions during the AGM by August 27, 2026.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has announced the record date for the purpose of dividend and AGM, with the 59th AGM scheduled for September 3, 2026, and the record date set for August 27, 2026. The company also notified the payment of final dividend to eligible members by September 27, 2026.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with sales up 7% and PAT up 45% compared to the same period last year.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with a profit before tax of ₹12,912 lakhs, a 9.3% increase from the previous quarter's ₹11,811 lakhs. The company's total income was ₹37,459 lakhs, a 0.4% increase from the previous quarter's ₹37,045 lakhs. Expenses for the quarter were ₹27,027 lakhs, a 12.1% decrease from the previous quarter's ₹30,727 lakhs.

Procter & Gamble Health Ltd

Procter & Gamble Health Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹3,637.7 lakhs, total income at ₹36,759 lakhs, and profit before tax at ₹12,912 lakhs.